Professor of Hematology and Oncology, Sungkyunkwan University School of Medicine

Speciality Interests

malignant lymphoma, CAR T-Cell therapy

Schedule

schedule of week
07 MON
22
TUE
23
WEN
24
THU
25
FRI
26
AM available available
PM available

Medical School

Ph.D. in Medicine College of Medicine, Seoul National University Master of Science College of Medicine, Seoul National University

Specialty Training

Specialty Training
Fellowship   1996~1997 Fellowship Section of Medical Oncology, Dept. of Internal Medicine, Samsung Medical Center. Seoul, Korea
1995~1996 Fellowship Section of Medical Oncology, Dept. of Internal Medicine, Seoul National University Hospital
Residency   1991~1995 Residency Dept. of Internal Medicine, Seoul National University Hospital
Internship   1990~1991 Internship Seoul National University Hospital

Other Education

  • 2010~present Professor Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center,Sungkyunkwan University, School of Medicine Seoul, Korea
    2004~2010 Associate Professor Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center,Sungkyunkwan University, School of Medicine Seoul, Korea
    2000~2004 Assistant Professor Division of Hematology-Oncology, Dept.of Medicine, Samsung Medical Center,Sungkyunkwan University, School of Medicine Seoul, Korea
    1998~2000 Full-time lecturer Division of Hematology-Oncology, Dept. of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea
    1997~1998 Staff Division of Hematology-Oncology, Dept. of Medicine, Samsung Medical Center, Seoul, Korea

Participation in Academic Societies
and Research

  • Member Korean Medical Association
    Member Korean Association of Internal Medicine
    Member Korean Society of Hematology
    Chairman lymphoma working party of Korean society of hematology
    Chairman Consortium of improving survival of lymphoma ( CISL)
    Founding member Asian lymphoma study group ( ALSG)
    Co-Chair T cell lymphoma forum (TCLF)

Thesis

BLOOD ADV 2021 10.1182/bloodadvances.2020004074

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Tam1, CS; Opat, S; Simpson, D; Cull, G; Munoz, J; Phillips, TJ; Kim, WS; Rule, S; Atwal, SK; Wei, R; Novotny, W; Huang, J; Wang, M; Trotman, J

LANCET HAEMATOL 2021

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Straus1, DJ; Dlugosz-Danecka, M; Connors, JM; Alekseev, S; Illes, A; Picardi, M; Lech-Maranda, E; Feldman, T; Smolewski, P; Savage, KJ; Bartlett, NL; Walewski, J; Ramchandren, R; Zinzani, PL; Hutchings, M; Munoz, J; Lee, HJ; Kim, WS; Advani, R; Ansell, SM; Younes, A; Gallamini, A; Liu, R; Little, M; Fenton, K; Fanale, M; Radford, J

ANTIVIR RES 2021 10.1016/j.antiviral.2021.105063

Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications

Kim1, JH; Kim, WS; Park, C

CANCER MANAG RES 2021 10.2147/CMAR.S309092

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma

Lee1, YP; Hong, JY; Yoon, SE; Cho, J; Shim, JH; Bang, Y; Kim, WS; Kim, SJ

KOREAN J INTERN MED 2021 10.3904/kjim.2019.367

Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia

Cho1, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ

CLOSE

Patients' Rights and Responsibilities

Patients' Rights

1. Right to receive medical care

Patients have the right to receive proper care in a safe setting without discrimination nor should their right to care be violated regardless of their gender, age, religion, social status, nationality, language, race, or physical/mental/financial status. Medical teams shall not refuse to provide care without justifiable reason.

2. Right to be informed and to make an autonomous decision

Patients have the right to obtain full and complete information from their medical team, to ask questions, and to determine their agreement or refusal concerning: diagnosis, treatment (purpose, plans and methods), outcomes of care (including unanticipated outcomes), discharge plan, participation in medical research studies, organ transplantation/donation, etc. Within ethical boundaries, patients may discontinue or refuse treatment, request that the medical team explain and suggest alternative treatments, and reserve the right to make their own decisions.

3. Right to confidentiality

Patients' rights to confidentiality regarding their physical/health status and privacy will not be violated. Patients can expect that all medical records/reports and their personal privacy will be kept confidential unless the patient has given consent or disclosure is permitted by law. To ensure their privacy, patients may be informed that Individuals not directly involved in their care may not be present and that the number of guardians accompanying patients to consultation rooms may be limited.

4. Right to request consultation and mediation

In the event of a medical dispute, patients may request consultation and mediation from an internal or external agency (Korea Consumer Agency, Korea Medical Dispute Mediation and Arbitration Agency).

5. Right to have values and beliefs respected

Patients will not be discriminated against because of their culture, religious values, or beliefs, and their rights will not be violated.

6. Right to receive care in a safe setting

Patients have the right to receive hospital-provided care where the patient’s medical information is protected and patient safety can be assured. In addition, patients have the right to be protected from possible dangers that can occur in a hospital and to have stability of mind and body.

Patients' Responsibilities

1. Responsibility to trust and respect the medical team

Patients must accurately inform the medical team of their health condition and must trust and respect the medical team's treatment plan. Patients may be responsible for consequences that result from not following instructions.

2. Responsibility to not use dishonest methods for medical treatment

Patients must reveal their identity before receiving any medical care and must not use false or dishonest methods, such as seeking medical care under disguised ownership.

3. Responsibility to abide by all hospital regulations

Patients are expected to treat all hospital staff and other patients with courtesy and respect; to abide by all hospital rules; and to earnestly fulfill their financial obligation to the hospital. Also, patients and their family members are expected to participate in all safety regulations.